PL353954A1 - Formulations for parenteral use of estramustine phosphate with improved pharmacological properties - Google Patents

Formulations for parenteral use of estramustine phosphate with improved pharmacological properties

Info

Publication number
PL353954A1
PL353954A1 PL00353954A PL35395400A PL353954A1 PL 353954 A1 PL353954 A1 PL 353954A1 PL 00353954 A PL00353954 A PL 00353954A PL 35395400 A PL35395400 A PL 35395400A PL 353954 A1 PL353954 A1 PL 353954A1
Authority
PL
Poland
Prior art keywords
formulations
pharmacological properties
parenteral use
estramustine phosphate
improved pharmacological
Prior art date
Application number
PL00353954A
Other languages
Polish (pl)
Inventor
LorenaMuggetti Lorena Muggetti
PaoloColombo Paolo Colombo
AlessandroMartini Alessandro Martini
GiovanniBuzzi Giovanni Buzzi
Original Assignee
Pharmacia Italia S.P.A.Pharmacia Italia S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia S.P.A.Pharmacia Italia S.P.A. filed Critical Pharmacia Italia S.P.A.Pharmacia Italia S.P.A.
Publication of PL353954A1 publication Critical patent/PL353954A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL00353954A 1999-09-16 2000-08-03 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties PL353954A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9921954.5A GB9921954D0 (en) 1999-09-16 1999-09-16 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
PCT/EP2000/007679 WO2001019338A1 (en) 1999-09-16 2000-08-03 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties

Publications (1)

Publication Number Publication Date
PL353954A1 true PL353954A1 (en) 2003-12-15

Family

ID=10861066

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00353954A PL353954A1 (en) 1999-09-16 2000-08-03 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties

Country Status (20)

Country Link
EP (1) EP1212040A1 (en)
JP (1) JP2003509355A (en)
KR (1) KR20020059405A (en)
CN (1) CN1177583C (en)
AU (1) AU777763B2 (en)
BR (1) BR0014063A (en)
CA (1) CA2385063A1 (en)
CZ (1) CZ2002943A3 (en)
EA (1) EA005308B1 (en)
GB (1) GB9921954D0 (en)
HK (1) HK1047227A1 (en)
HU (1) HUP0202621A2 (en)
IL (1) IL148409A0 (en)
MX (1) MXPA02002859A (en)
NO (1) NO20021306L (en)
NZ (1) NZ517631A (en)
PL (1) PL353954A1 (en)
SK (1) SK3452002A3 (en)
WO (1) WO2001019338A1 (en)
ZA (1) ZA200201743B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658913B2 (en) 2005-11-28 2010-02-09 Verrow Pharmaceuticals, Inc. Compositions useful for reducing nephrotoxicity and methods of use thereof
WO2012037704A1 (en) 2010-09-21 2012-03-29 Telefonaktiebolaget L M Ericsson (Publ) Air-interface timing synchronization sharing
WO2019094819A2 (en) * 2017-11-09 2019-05-16 Abon Pharmaceuticals, Llc Intravenous delivery systems for chemotherapy drugs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59108800A (en) * 1982-12-13 1984-06-23 Japan Atom Energy Res Inst Fine particle having guided missile action and slow-releasing function of carcinostatic agent
KR0166088B1 (en) * 1990-01-23 1999-01-15 . Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
GB9419153D0 (en) * 1994-09-22 1994-11-09 Erba Carlo Spa Estramustine formulations with improved pharmaceutical properties
US20020039594A1 (en) * 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same

Also Published As

Publication number Publication date
MXPA02002859A (en) 2003-07-21
BR0014063A (en) 2004-06-29
EP1212040A1 (en) 2002-06-12
WO2001019338A1 (en) 2001-03-22
JP2003509355A (en) 2003-03-11
CN1374858A (en) 2002-10-16
IL148409A0 (en) 2002-09-12
NZ517631A (en) 2004-01-30
KR20020059405A (en) 2002-07-12
CA2385063A1 (en) 2001-03-22
CN1177583C (en) 2004-12-01
EA005308B1 (en) 2004-12-30
AU777763B2 (en) 2004-10-28
CZ2002943A3 (en) 2002-08-14
NO20021306D0 (en) 2002-03-15
GB9921954D0 (en) 1999-11-17
HUP0202621A2 (en) 2002-12-28
ZA200201743B (en) 2003-05-28
HK1047227A1 (en) 2003-02-14
AU6836300A (en) 2001-04-17
NO20021306L (en) 2002-04-24
SK3452002A3 (en) 2002-08-06
EA200200369A1 (en) 2002-08-29

Similar Documents

Publication Publication Date Title
GB9921954D0 (en) Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
GB9921958D0 (en) Formulations for parenteral use of estramustine phosphate and sulfoalkylether-cyclodextrins
PL352409A1 (en) Derivatives of 1-trifluorometyl-4-hydroxy-7-piperidinyl-aminomethylochromane
HUP0202645A3 (en) Fornulations for parenteral use of estramustine phosphate and albumin
GB9900215D0 (en) Structure of vehicles
HUP0203384A3 (en) Process for the preparation of ketimines
TW435837U (en) Structure improvement of connector
IL149527A0 (en) Process for the preparation of ketimines
TW395176U (en) Structure of designed article
TW411904U (en) Improvement of displacement structure for mold socket
TW437318U (en) Assembly structure of main decorative body for decorative article
GB9918779D0 (en) Formulations for parenteral use of estramustine phosphate and albumin
TW403237U (en) Improvement of socket structure
TW422240U (en) Knock set for anti-thieving lock
TW420132U (en) Improved structure of pivoting for box body
AU141959S (en) Set of vehicle bumperettes
TW414404U (en) Structure improvement of connector
TW367864U (en) Improvement for transmission structure of mini-stepper
TW374536U (en) Improved structure for the hanger of the earphone
TW424959U (en) Structure improvement of SMA connector
IL128359A0 (en) Methods for the preparation of erythromycin derivatives
TW430178U (en) Improved multi-hole socket structure
GB9916989D0 (en) Control of male fertility
TW400884U (en) Improvement of lock structure
AU2954000A (en) The pharmacological use of certain cystine derivatives

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)